Cabergoline .5mg

Description

Cabergoline .5mg  per ml x 30ml

In the early 1980’s, Cabergoline was discovered by an Italian drug company Farmitalia Carlo Erba, which now Pfizer runs. Scientists discovered the drug while experimenting with ergot (fungus) alkaloids. The FDA approved the drug in 1996, and it went generic in 2005 after its patent expired in the US.

How Cabergoline works:

Cabergoline is a synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. It exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control.

In addition, receptor-binding studies indicate that Cabergoline has low affinity for dopamine D1, α1- and α2-adrenergic, and 5-HT1- and 5-HT2-serotonin receptors. In conclusion, it decreased serum prolactin levels in reserpinized rats.

Possible Benefits:

Cabergoline offers use in clinical and research settings for different types of medical problems that occur when too much of the hormone prolactin is produced. Firstly, its potential benefits for use include menstrual problems, fertility and sexual problems in men and women, and increase in testosterone.

• possesses antioxidant and neuroprotective properties due to its free radical scavenging activity

Molecular Formula:    C26H37N5O2

Molecular Mass:         451.6 g/mol

Chemical Name:         1-[(6-allylergolin-8ß-yl)-carbonyl]-1-[3-(dimethylamino) propyl]-3-ethylurea